
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet has demonstrated significant growth momentum, achieving record new customer starts in the fourth quarter of 2025, with notable year-over-year and sequential acceleration in both the U.S. and international markets. The company reported revenues of $784 million for Q4, marking a 31% increase year-over-year, driven by strong volume growth, enhanced manufacturing productivity, and favorable pricing dynamics from existing customer transitions. Additionally, Insulet's proactive investment strategy is evidenced by a capital expenditure increase to $135 million, aimed at expanding manufacturing capacity and developing future facilities, reinforcing its commitment to meet rising demand.
Bears say
Insulet's stock faces a negative outlook primarily due to sustained poor sentiment within the therapeutic sector, particularly as competitors trade at historically low levels, reflecting concerns over accelerated GLP-1 adoption impacting demand. Additionally, the company's growth estimates for the US Omnipod have shown modest projections of 20-22%, while faced with a significant decline of approximately 50% in the drug delivery segment, indicating vulnerability in core business areas. The overarching risks, including heightened competition in the pump market and potential delays in pipeline product approvals, further contribute to the negative sentiment surrounding Insulet’s financial projections.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares